Table 2.
Comparison of characteristics between the present study and two main references
| Present study | Park et al. (2016) [9] | Alyami et al. (2021) [10] | |
|---|---|---|---|
| Patient selection | Patients with germline TP53 mutation (2011-2022) | Patients with germline TP53 mutation (2003-2015) | Patients with breast cancer with germline TP53 mutation (2005-2019) |
| No. of patients | 14 | 14 | 12 |
| F:M | 13:1 | 11:3 | 12:0 |
| Age at first diagnosis (yr), median (range) | 32 (1-67) | 25 | 33.5 (20-52) |
| Multiple primary cancer, n (%) | 7 (50.0) | 11 (78.6) | 9 (75.0) |
| Breast cancer | 9 (64.3) | 6 (42.9) | 12 (100) |
| Sarcoma | 5 (35.7) | 5 (35.7) | 1 (8.3) |
| Thyroid cancer | 3 (21.4) | 2 (14.3) | 2 (16.7) |
| Pancreatic cancer | 2 (14.3) | 0 | 1 (8.3) |
| Brain tumor | 1 (7.1) | 4 (28.6) | 0 |
| Adrenocortical carcinoma | 1 (7.1) | 1 (7.1) | 0 |
| Ovarian cancer | 1 (7.1) | 0 | 0 |
| Endometrial cancer | 1 (7.1) | 0 | 0 |
| Colon cancer | 1 (7.1) | 0 | 1 (8.3) |
| Vaginal cancer | 1 (7.1) | 0 | 0 |
| Skin cancer | 1 (7.1) | 2 (14.3) | 1 (8.3) |
| Leukemia | 1 (7.1) | 2 (14.3) | 0 |
| Lung cancer | 0 | 2 (14.3) | 4 (33.3) |
| Stomach cancer | 0 | 2 (14.3) | 1 (8.3) |
| Nasal cavity cancer | 0 | 1 (7.1) | 1 (8.3) |
| Lymphoma | 0 | 0 | 3 (25.0) |
F, female; M, male.